OncoFirm™ / Whitepapers / Fluorescent LFA vs. traditional testing
Whitepaper · For healthcare systems
Fluorescent LFA vs. Traditional Testing: A Guide for Healthcare Systems
Health systems are being asked to diagnose earlier, closer to the patient and at lower total cost. This guide compares central-laboratory testing, visual rapid tests and quantitative fluorescent lateral flow assays (FLFA), explains where each fits in a cancer care pathway, and sets out what to validate before bringing a point-of-care biomarker test into service.
At a glance
Written for
Health system leaders, laboratory directors, clinicians and global health programs
Compares
Central-lab immunoassay · visual rapid test · fluorescent LFA
Key point
Fluorescent LFA can bring quantitative results to the point of care; each assay must prove its own performance
OncoFirm™ focus
Self-calibrating fluorescent strip and handheld reader, starting with CEA and PSA
Status
In development · not FDA cleared or approved · research use only first
On this page
Three ways to test
Central lab, visual rapid test or fluorescent LFA?
Fluorescent lateral flow assays use the same paper-strip format as a rapid test, but with fluorescent labels that a handheld reader measures. The result is a number, produced near the patient in minutes, rather than a colored line judged by eye or a sample sent to a central laboratory.
| Consideration | Central-lab immunoassay | Visual rapid test | Fluorescent LFA (OncoFirm™) |
|---|---|---|---|
| Where it runs | Central or hospital laboratory | At the point of care, read by eye | At the point of care, read by a handheld reader |
| Time to result | Hours to days, including transport and batching | Minutes | Minutes (design target ≤ 20 min) |
| Result | Quantitative value | Usually yes/no | Quantitative value, e.g. ng/mL |
| Equipment and staff | Analyzers, laboratory scientists | None beyond the strip | One handheld reader, trained operators |
| Calibration | Analyzer calibration and controls | None | Reference line on every strip plus lot calibration |
| Multiplexing | Broad, across many analyzers | Limited | Designed for panels on one strip |
| Data | Laboratory information system | Recorded by hand | Digital record ready for LIS/EHR interfaces |
| Best fit | High volume, broad menus, confirmation | Simple yes/no decisions | Quantitative results needed during the visit |
OncoFirm™ column describes design goals for a platform in development, not demonstrated performance.
For the detection chemistry behind the comparison, see fluorescent vs. gold nanoparticle assays and how lateral flow assays work.
Patient pathway
What changes for the patient and the care team
The laboratory route separates the sample from the decision by hours or days, often across two visits. A validated point-of-care quantitative test is designed to put the number in front of the clinician during the same visit. Illustration of intended workflow.
Where it fits
Where fluorescent LFA can add value in a health system
Oncology follow-up
Serial tumor-marker checks such as CEA between visits, with results available at the appointment rather than afterwards.
Primary care and community clinics
Quantitative results in practices without on-site laboratories, with a digital record sent back to the health system.
Rural and mobile programs
Testing where courier times or cold chains make central-lab turnaround impractical.
Global health
Settings with limited laboratory capacity, part of the case made in the global need for affordable early cancer diagnostics.
More on decentralized testing: point-of-care oncology.
Scope
What fluorescent LFA does not replace
- Confirmatory laboratory testing when a result will change treatment.
- Imaging, endoscopy and biopsy, which remain the basis of cancer diagnosis.
- Guideline-based screening. CEA is a monitoring marker, not a population screening test, and PSA testing follows shared decision-making guidelines.
- Broad laboratory menus and high-volume batch work, where central analyzers are more efficient.
Implementation checklist
Six questions before bringing a point-of-care biomarker test into service
01
Clinical question
Which decision will the result change, for which patients, and at what point in the pathway?
02
Evidence and status
Analytical validation, method comparison with your laboratory assay, clinical evaluation, FDA status and CLIA categorization.
03
Quality control
On-strip reference and control lines, lot calibration, external controls and proficiency testing.
04
People and training
Operator competency, sample collection technique and clear escalation rules.
05
Connectivity
Results flowing to the laboratory information system and health record through standard interfaces such as HL7.
06
Governance
Data privacy, device management, ownership of results and audit trails.
Cost and value
Count the whole pathway, not just the price per test
A point-of-care test usually costs more per result than a high-volume laboratory assay. The comparison that matters for a health system is the cost of the whole pathway:
- Sample transport, batching and result follow-up
- Return visits needed only to discuss a result
- Patients lost to follow-up between the test and the decision
- Time from first contact to treatment decision
- Reader cost shared across every assay on the same device
These are the endpoints worth measuring in pilot studies and health-economic evaluations.
OncoFirm™ approach
How OncoFirm™ is building fluorescent LFA for health systems
Self-calibrating strip
Test, reference and control lines on every strip; the test-to-reference ratio corrects drift inside each test. Platform
Handheld reader
Whole-strip, timed reads with run-quality flags and a digital record. Digital readers · OncoFirm™ reader
Traceable calibration
Calibration planned to trace to WHO reference materials for CEA (NIBSC 73/601) and PSA (NIBSC 17/100).
Decision support
Validated software for quality checks and trend display, with clinicians in charge. AI-assisted diagnostics
Research
Tumor antigens and panels
Multiplex panels and tumor-associated antigens such as the Thomsen–Friedenreich antigen.
FAQ
Frequently asked questions
What is the difference between fluorescent lateral flow and traditional laboratory testing?
Traditional testing runs samples on large analyzers in a central laboratory, with results in hours to days. Fluorescent lateral flow runs a single test on a paper strip near the patient, and a handheld reader measures the glowing test line to give a quantitative result in minutes.
Is fluorescent lateral flow as accurate as a laboratory immunoassay?
It depends on the specific assay. Each test has to show its own precision, detection limits and agreement with an established laboratory method in validation studies. Fluorescent detection makes laboratory-like quantitation possible in a rapid format, but it does not guarantee it.
Can fluorescent lateral flow tests replace the central laboratory?
No. They are designed to complement it: bringing selected, well-validated measurements closer to the patient while confirmatory testing, complex panels and high-volume work stay in the laboratory.
Can CEA or PSA rapid tests be used for cancer screening?
CEA is used mainly to monitor known colorectal cancer, not to screen the general population. PSA testing for prostate cancer follows guideline-based shared decision-making. Any OncoFirm assay will carry an intended use defined by its validation and regulatory review.
What does a health system need to run fluorescent point-of-care tests?
A handheld reader, trained operators, a quality-control plan, connectivity to the laboratory or health record system and the regulatory and CLIA status that matches where the test will be used.
Are OncoFirm fluorescent tests available to order?
Not yet. The platform and its assays are in development, are not cleared or approved by the FDA and are not available for sale. First products are planned for research use only.
Keep reading
Related guides
Sources
References
- Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Analytical and Bioanalytical Chemistry. 2009;393:569–582. doi.org/10.1007/s00216-008-2287-2
- Bahadır EB, Sezgintürk MK. Lateral flow assays: principles, designs and labels. TrAC Trends in Analytical Chemistry. 2016;82:286–306. doi.org/10.1016/j.trac.2016.06.006
- National Cancer Institute. Tumor Markers. www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
- U.S. Food and Drug Administration. CLIA Categorizations. www.fda.gov/medical-devices/ivd-regulatory-assistance/clia-categorizations
- U.S. Food and Drug Administration. In Vitro Diagnostics. www.fda.gov/medical-devices/products-and-medical-procedures/in-vitro-diagnostics
- World Health Organization. Guide to cancer early diagnosis. Geneva: WHO; 2017. www.who.int/publications/i/item/9789241511940
Development status. The OncoFirm™ fluorescent platform and its assays are in development. They have not been cleared or approved by the FDA and are not available for sale. First products are planned for research use only. Comparisons describe design goals, not demonstrated performance.
Talk to us about pilots, partnerships and distribution
Health systems, laboratories and global health programs can help shape validation and pilot studies. Collaboration inquiry · Distributor inquiry · Investor inquiry